Quarterly report pursuant to Section 13 or 15(d)

Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)

v3.21.2
Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
May 08, 2021
USD ($)
$ / shares
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Jun. 30, 2021
USD ($)
segment
shares
Jun. 30, 2020
USD ($)
shares
Dec. 31, 2020
USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                
Number of operating segments | segment           1    
Number of reportable segments | segment           1    
Net loss   $ 7,888 $ 5,177 $ 3,136 $ 3,271 $ 13,065 $ 6,407  
Net cash used in operating activities           9,919 $ 6,479  
Accumulated deficit   (83,649)       (83,649)   $ (70,584)
Working capital   17,700       17,700    
Cash balance   $ 20,800       $ 20,800    
Amount of options to purchase (in shares) | shares           4,266,275 3,316,050  
Amount of warrants to purchase (in shares) | shares           529,141 1,324,608  
Amount of unvested restricted stock (in shares) | shares           283,348 133,340  
Merger Agreement | AbbVie Inc.                
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                
Merger related costs, cash paid per share | $ / shares $ 22.60              
Termination fees $ 18,600              
Reverse termination fees $ 20,000